Cortagen Dosage Guide

Evidence-based protocols for the cerebral cortex bioregulator peptide — Khavinson bioregulator paradigm, neuroprotection, cognitive enhancement, cycling, stacking, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

Cortagen

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is Cortagen?

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to the Khavinson bioregulator peptide family — a class of short synthetic peptides (2–4 amino acids) theorized to regulate gene expression in specific tissue types. Other members of this family include Epitalon (pineal gland), Pinealon (brain), Vilon (immune system), and Thymalin (thymus).

Cortagen is specific to cerebral cortex tissue. According to Khavinson's research, it interacts with DNA in cortical neurons to modulate protein synthesis and normalize cellular function at the gene expression level. The proposed mechanisms include regulation of cortical neuron gene expression, neuroprotective effects against oxidative stress, enhancement of cognitive function through cortical optimization, and normalization of cortical bioelectrical activity (EEG patterns).

This is a fundamentally different paradigm from most Western peptide therapeutics. While peptides like Semax work through acute receptor-mediated signaling (melanocortin receptors, BDNF upregulation), Cortagen is theorized to work by directly influencing gene expression in target tissue — producing effects that develop over the course of a 10–20 day cycle and persist for months afterward. This bioregulator paradigm is the foundation of Khavinson's broader anti-aging research program.

Use our Peptide Dosage to calculate your exact dose based on vial size and concentration.

Dosing information in this guide is derived from published research and established protocols — not from approved pharmaceutical labeling and community protocols.

Key Characteristics:

Cerebral cortex bioregulator — a short tetrapeptide (Ala-Glu-Asp-Pro) specific to cortical neurons, theorized to modulate gene expression in cerebral cortex tissue
Khavinson bioregulator family — part of the same peptide paradigm as Epitalon, Pinealon, and Vilon — short peptides targeting tissue-specific gene expression
Short-cycle protocol — administered for 10–20 consecutive days, repeated every 3–6 months — identical to the Epitalon paradigm
Neuroprotective mechanisms — proposed to protect cortical neurons against oxidative stress, normalize bioelectrical activity, and support cognitive function
Short plasma half-life — cleared from plasma within minutes, but bioregulatory effects on gene expression are theorized to persist for months
Multiple administration routes — subcutaneous injection (primary), intranasal (some protocols), oral capsules (available in Russia)

For related bioregulator peptides, see our Epitalon profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Cortagen Dosage Is Determined

Cortagen dosing is based on research published by Khavinson's group and clinical protocols used within the Russian healthcare system. Unlike many Western peptide therapeutics that have extensive dose-response studies in diverse populations, Cortagen dosing derives primarily from a smaller body of Russian/CIS research. It is important to be transparent about this evidence base when evaluating protocols.

The Bioregulator Dosing Paradigm

Khavinson's bioregulator peptides follow a distinct dosing philosophy that differs from conventional pharmacology. Rather than titrating to a steady-state plasma concentration, the protocol uses short intensive courses (10–20 days) designed to trigger lasting changes in gene expression. The hypothesis is that these short peptides enter cells, interact with specific DNA sequences, and modulate protein synthesis in their target tissue — effects that persist long after the peptide itself has been cleared from the body.

Published Dosage Parameters

Khavinson and colleagues have published Cortagen protocols using 1–10 mg administered subcutaneously once daily for courses of 10–20 days. The research literature reports doses stratified by intended application: lower doses (1–3 mg) for general nootropic and cognitive maintenance purposes, and higher doses (5–10 mg) for neurological support in contexts such as age-related cognitive decline, cerebrovascular recovery, and post-traumatic brain injury rehabilitation.

Oral Bioavailability Research

Khavinson's group has published research suggesting that bioregulator tetrapeptides retain biological activity when administered orally. The hypothesis is that peptides of 2–4 amino acids are small enough to resist complete enzymatic degradation in the GI tract and maintain sufficient bioavailability for gene-regulatory effects. Oral Cortagen capsules (10 mg) are available in Russia and are taken 1–2 times daily for 10–30 days. However, subcutaneous injection remains the preferred route in research settings due to more predictable bioavailability.

EEG and Cognitive Studies

Research by Khavinson and colleagues has examined Cortagen's effects on cortical bioelectrical activity using electroencephalography (EEG). Published studies report normalization of EEG patterns in elderly subjects and individuals with cerebrovascular disorders following 10–20 day Cortagen courses at standard doses. Cognitive assessments in these studies reported improvements in memory, attention, and mental performance scores.

Strength of evidence: Moderate-to-limited. Cortagen has published research in peer-reviewed journals, including some international publications. However, the majority of studies originate from Khavinson's group and Russian/CIS institutions. There are no large-scale, randomized, placebo-controlled trials conducted by independent Western research groups. The bioregulator peptide paradigm itself — short peptides directly modulating gene expression in tissue-specific ways — is not widely accepted in mainstream Western pharmacology. Users should weigh this evidence context when making decisions.

Standard Cortagen Dosage Ranges

Cortagen is administered by subcutaneous injection (primary route), with intranasal and oral capsule alternatives available. All protocols follow the intensive short-cycle model: daily administration for 10–20 days, followed by a 3–6 month break before repeating.

Subcutaneous Injection Protocols

Protocol	Daily Dose	Cycle Duration	Repeat Interval	Notes
Nootropic / Maintenance	1–3 mg SubQ	10–20 days	Every 3–6 months	Standard cognitive support; most common starting protocol
Neurological Support	5–10 mg SubQ	10–20 days	Every 3–6 months	Higher dose for age-related decline, cerebrovascular, or TBI recovery
Conservative Start	1 mg SubQ	10 days	Every 4–6 months	Recommended for first-time users to assess tolerance

Alternative Administration Routes

Route	Dose	Frequency	Cycle	Notes
Oral (capsules)	10 mg	1–2x daily	10–30 days	Available in Russia; longer cycles compensate for lower oral bioavailability
Intranasal	1–3 mg	1x daily	10–20 days	Some protocols use intranasal for direct CNS access; less data available

Administration Timing

Morning administration preferred: Cortagen targets cortical function and cognitive performance; morning dosing aligns with the active waking period
Fasting not strictly required: Unlike GHRPs, Cortagen's bioregulatory mechanism does not depend on GH release or blood glucose levels. However, some practitioners recommend fasted administration for consistency
Consistent daily timing: Administer at the same time each day throughout the 10–20 day cycle for consistent tissue exposure
Single daily injection: Most protocols use one injection per day. Some higher-dose protocols split the daily dose into two administrations (morning and early afternoon)

Do not exceed 10 mg per day. Published Cortagen protocols use a maximum of 10 mg daily. Doses above this have not been studied. The bioregulator paradigm relies on signaling at physiological concentrations — higher doses do not necessarily produce greater gene expression effects.

Khavinson Bioregulator Peptide Comparison

Cortagen is one member of a larger family of Khavinson bioregulator peptides, each targeting specific tissue types. Understanding where Cortagen fits within this family helps inform protocol design, especially for users interested in multi-tissue longevity stacks.

Peptide	Sequence	Target Tissue	Primary Effect	Cycle Protocol
Cortagen	Ala-Glu-Asp-Pro	Cerebral cortex	Cortical neuroprotection, cognitive enhancement	1–10 mg/day, 10–20 days
Epitalon	Ala-Glu-Asp-Gly	Pineal gland	Telomerase activation, melatonin restoration	5–10 mg/day, 10–20 days
Pinealon	Glu-Asp-Arg	Brain (general)	Central nervous system regulation, neuroprotection	10–20 mg/day, 10–20 days
Vilon	Lys-Glu	Immune system	Immune modulation, thymic function	1–5 mg/day, 10–20 days
Thymalin	Polypeptide extract	Thymus	Immune reconstitution, thymic regeneration	5–10 mg/day, 10–14 days
Cardiogen	Ala-Glu-Asp-Arg	Heart	Cardiac tissue regeneration, cardioprotection	1–10 mg/day, 10–20 days

Key distinction: All Khavinson bioregulators share the same cycling paradigm (10–20 day intensive courses, repeated every 3–6 months) and the same proposed mechanism (tissue-specific gene expression modulation). What differentiates them is their tissue specificity. Cortagen is uniquely targeted to cerebral cortex neurons, making it the bioregulator of choice for cortical cognitive function and neuroprotection.

Calculate Your Cortagen Dose

Cortagen is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg or 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe. The concentration depends on how much water you add to the vial.

Worked Example:

Vial size: 10 mg (10,000 mcg) of Cortagen
Bacteriostatic water added: 2 mL
Concentration: 10,000 mcg ÷ 2 mL = 5,000 mcg per mL (5 mg/mL)
Target dose: 3 mg (3,000 mcg)
Volume to draw: 3,000 ÷ 5,000 = 0.6 mL = 60 units on an insulin syringe

Quick Reference — 10 mg Vial

Bac Water Added	Concentration	1 mg Dose	3 mg Dose	5 mg Dose
1 mL	10 mg/mL	10 units (0.1 mL)	30 units (0.3 mL)	50 units (0.5 mL)
2 mL	5 mg/mL	20 units (0.2 mL)	60 units (0.6 mL)	100 units (1.0 mL)
2.5 mL	4 mg/mL	25 units (0.25 mL)	75 units (0.75 mL)	125 units (1.25 mL)

Quick Reference — 5 mg Vial

Bac Water Added	Concentration	1 mg Dose	3 mg Dose	5 mg Dose
1 mL	5 mg/mL	20 units (0.2 mL)	60 units (0.6 mL)	100 units (1.0 mL)
2 mL	2.5 mg/mL	40 units (0.4 mL)	120 units (1.2 mL)	Full vial

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

Cortagen Dosage by Goal

Cortagen protocols vary depending on the primary objective. The bioregulator paradigm means that all protocols follow the same basic structure (intensive daily dosing for 10–20 days, repeated every 3–6 months), but the dose and supporting compounds differ by goal.

General Cognitive Enhancement & Nootropic Support

For users seeking improved mental clarity, focus, and cognitive endurance. This is the most common Cortagen protocol and the recommended starting point for new users. Effects are typically subtle and cumulative rather than acute — expect gradual improvements in cognitive performance over the course of the cycle, with benefits persisting for months afterward.

Dose: 1–3 mg SubQ daily (morning)
Cycle: 10–20 consecutive days
Repeat: Every 4–6 months
Optional stack: + Semax (200–600 mcg intranasal daily) for complementary receptor-mediated nootropic effects

Age-Related Cognitive Decline

For older adults experiencing age-related cognitive changes. This protocol uses higher doses based on Khavinson's research in elderly populations, where Cortagen was studied in the context of age-related cortical function decline. Published studies reported improvements in memory, attention, and mental performance scores following 10–20 day courses.

Dose: 5–10 mg SubQ daily (morning)
Cycle: 10–20 consecutive days
Repeat: Every 3–6 months
Common stack: + Epitalon (5–10 mg SubQ daily) for combined cortical neuroprotection and pineal/telomerase benefits

Neurological Recovery (Cerebrovascular & TBI)

For individuals recovering from cerebrovascular events or traumatic brain injury. This represents the most intensive Cortagen protocol and should only be considered under medical supervision. Khavinson's research has examined Cortagen in these contexts within the Russian clinical system.

Dose: 5–10 mg SubQ daily
Cycle: 15–20 consecutive days
Repeat: Every 3–4 months (shorter intervals for active recovery)
Note: This protocol requires medical supervision. Do not self-administer for serious neurological conditions.

Medical supervision required: If you are dealing with cerebrovascular disease, traumatic brain injury, or any serious neurological condition, do not self-administer Cortagen without consulting a qualified healthcare provider. This guide is educational — it does not replace professional medical care.

Comprehensive Longevity & Anti-Aging

For users pursuing Khavinson's multi-tissue bioregulator approach to longevity. This protocol combines Cortagen with other bioregulator peptides for systemic anti-aging benefits. The theory is that addressing gene expression in multiple tissue types simultaneously produces synergistic longevity effects.

Cortagen: 3–5 mg SubQ daily for 10–20 days (cerebral cortex)
Epitalon: 5–10 mg SubQ daily for 10–20 days (pineal gland / telomerase)
Pinealon: 10–20 mg daily for 10–20 days (brain / CNS)
Repeat: Every 4–6 months as a coordinated cycle

Bioregulator effects are cumulative. Unlike acute-acting peptides, Cortagen's benefits are theorized to build with repeated cycles. Users of Khavinson bioregulators often report that the most significant improvements come after 2–3 complete cycles over 12–18 months, rather than from a single course.

Cycling Protocols

Cycling is fundamental to the Khavinson bioregulator paradigm. Unlike GHRPs where cycling prevents receptor desensitization, bioregulator cycling reflects the theory that short intensive courses trigger gene expression changes that persist for months. The off-period is not “recovery” — it is the period during which the bioregulatory effects are theorized to be actively working at the cellular level.

Protocol	On-Cycle	Off-Cycle	Cycles per Year	Best For
Standard	10 days	5–6 months off	2	General cognitive maintenance; most common protocol
Extended	20 days	4–6 months off	2–3	Neurological support; age-related decline; more intensive effect
Intensive	20 days	3–4 months off	3–4	Active neurological recovery (medical supervision recommended)
Longevity Stack	10–20 days (with other bioregulators)	4–6 months off	2–3	Multi-tissue anti-aging with Epitalon, Pinealon, etc.

Why Bioregulator Cycling Differs from GHRP Cycling

GHRPs like Hexarelin require cycling because continuous receptor stimulation causes desensitization — the pituitary becomes less responsive. Bioregulator peptides like Cortagen follow a different logic entirely: the short intensive course is designed to “reprogram” gene expression in the target tissue, and the months-long off-period is when these changes are theorized to be expressed and maintained. Running another course too soon is considered unnecessary, not harmful.

Patient consistency matters. Complete the full 10–20 day course without skipping days. The bioregulatory theory depends on sustained daily stimulation over the cycle period to trigger the gene expression cascade. Sporadic or inconsistent dosing during the on-cycle may reduce the effectiveness of the course.

Cortagen Stacking Protocols

Cortagen stacking leverages two approaches: combining with other Khavinson bioregulators for multi-tissue support (the paradigm's intended design), or combining with conventional nootropic peptides that work through complementary receptor-mediated mechanisms.

Cortagen + Epitalon — Cortex + Pineal Bioregulator Stack

The most popular Cortagen stack within the bioregulator community. Combines Cortagen's cortical neuroprotection with Epitalon's telomerase activation and melatonin restoration. Both peptides follow the same cycling paradigm and can be administered concurrently during the same 10–20 day course.

Compound	Dose	Frequency	Purpose
Cortagen	3–5 mg SubQ	1x daily (morning)	Cerebral cortex bioregulation, neuroprotection
Epitalon	5–10 mg SubQ	1x daily (morning or evening)	Pineal bioregulation, telomerase activation, melatonin

Protocol note: Cortagen and Epitalon can be administered at the same time as separate injections. Some practitioners inject Cortagen in the morning (to align with cognitive activity) and Epitalon in the evening (to align with melatonin production). Both approaches are used in published protocols.

Cortagen + Pinealon — Dual Brain Bioregulator Stack

Combines two brain-targeted bioregulators: Cortagen (specific to cerebral cortex) and Pinealon (broader CNS regulation). Khavinson's research suggests these target overlapping but distinct neural systems, potentially producing synergistic neuroprotective effects.

Compound	Dose	Frequency	Purpose
Cortagen	3–5 mg SubQ	1x daily (morning)	Cerebral cortex gene expression, cognitive enhancement
Pinealon	10–20 mg oral or SubQ	1x daily	Broader CNS regulation, neuronal protection

Cortagen + Semax — Bioregulator + Conventional Nootropic

Combines two fundamentally different nootropic paradigms: Cortagen's bioregulatory gene expression modulation with Semax's acute receptor-mediated nootropic effects (BDNF upregulation, melanocortin receptor activation). This stack addresses both long-term cortical optimization and acute cognitive performance.

Compound	Dose	Frequency	Purpose
Cortagen	1–5 mg SubQ	1x daily (morning), 10–20 day cycle	Long-term cortical bioregulation, gene expression modulation
Semax	200–600 mcg intranasal	1–3x daily (can extend beyond Cortagen cycle)	Acute BDNF upregulation, focus, cognitive performance

Cortagen + Cerebrolysin — Bioregulator + Neurotrophic

Combines Cortagen's gene expression modulation with Cerebrolysin's neurotrophic factor delivery. Cerebrolysin is a porcine brain-derived peptide preparation containing multiple neurotrophic factors. This is the most intensive neuroprotective stack and is typically used in neurological recovery contexts under medical supervision.

Compound	Dose	Frequency	Purpose
Cortagen	5–10 mg SubQ	1x daily, 10–20 day cycle	Cortical gene expression modulation, neuroprotection
Cerebrolysin	5–30 mL IV/IM	Daily or 5x/week, 10–20 day course	Neurotrophic factor delivery, neuronal repair

The Cortagen + Cerebrolysin stack requires medical supervision. Cerebrolysin is a prescription medication in many countries and is administered intravenously or intramuscularly. Do not attempt this stack without qualified medical guidance. It is listed here for educational completeness.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile: Cortagen has an extremely mild side effect profile based on available data. The Khavinson bioregulator peptides as a class have been used in Russian clinical practice for several decades with very favorable safety reports. However, long-term safety data from independent Western studies is lacking, and the evidence base is narrower than for more extensively studied peptides.

Reported Side Effects

Rare and generally mild:

Injection site reactions — mild redness, slight soreness, or minor swelling at the injection site; resolves quickly
Mild headache — occasionally reported in the first few days of a cycle; typically resolves spontaneously
Mild fatigue or drowsiness — infrequently reported; usually transient during the first 2–3 days

Notably absent compared to many peptides:

No hormonal disruption (no cortisol, prolactin, or GH axis effects)
No appetite changes
No water retention or bloating
No known desensitization or tolerance development
No reported cardiovascular effects

The bioregulator peptide safety advantage. Khavinson's bioregulator peptides (including Cortagen, Epitalon, and Pinealon) have consistently demonstrated very mild side effect profiles across published research and decades of Russian clinical use. Their short amino acid sequences (2–4 residues) result in low immunogenicity and rapid clearance. However, “low reported side effects” should be interpreted in the context of the available evidence base — which is smaller and less independently replicated than for many Western peptide therapeutics.

Contraindications

Known allergy to component amino acids — Cortagen consists of Ala-Glu-Asp-Pro. Hypersensitivity to any component is a contraindication, though allergic reactions to such short peptides are extremely rare.
Pregnancy and breastfeeding — no safety data exists for Cortagen during pregnancy or nursing. Avoid entirely.
Active brain tumors or CNS malignancies — Cortagen is theorized to modulate gene expression in cortical neurons. While no evidence suggests tumor-promoting effects, use in the context of active CNS malignancy is contraindicated as a precaution.
Autoimmune neurological conditions — conditions such as multiple sclerosis or autoimmune encephalitis involve dysregulated immune activity in the CNS. The effects of Cortagen on gene expression in this context are unknown. Use with medical supervision only.
Children and adolescents — Cortagen has not been studied in pediatric populations. The developing brain has different gene expression requirements. Avoid use in individuals under 18.

When to Stop or Reduce Dose

Any allergic reaction (rash, swelling, difficulty breathing) — discontinue immediately
Persistent headaches that do not resolve after 3–4 days of the cycle
Unusual neurological symptoms (confusion, visual disturbance, persistent dizziness) — discontinue and consult a healthcare provider
Any symptom that feels concerning or unusual — err on the side of caution

Regulatory Status: Cortagen is not FDA-approved for any indication. In Russia, it is available as a dietary supplement and has been used in clinical practice. In most Western countries, it is classified as a research peptide / research chemical. It is not approved for human therapeutic use by the FDA, EMA, or other major Western regulatory agencies. Verify your local regulations before purchasing.

Common Cortagen Dosing Mistakes

Avoid these common errors to get the most out of your Cortagen protocol:

Using Cortagen continuously instead of cycling: Khavinson bioregulator peptides are designed for short intensive cycles (10–20 days), not continuous daily use. The bioregulatory effects on gene expression are theorized to persist for months after the cycle. Continuous use has not been studied and does not follow the established protocol.

Expecting immediate nootropic effects like a stimulant: Cortagen is not a stimulant or an acute cognitive enhancer. As a bioregulator, it is theorized to work by gradually modulating gene expression in cortical neurons. Effects may become noticeable over the course of the 10–20 day cycle and are often subtle — improved mental clarity, cognitive endurance, or neuroprotective benefits rather than acute stimulation.

Equating Cortagen with conventional nootropic peptides like Semax: Cortagen and Semax operate through fundamentally different paradigms. Semax works via acute receptor-mediated signaling (melanocortin receptors, BDNF upregulation) with effects within hours. Cortagen works through the bioregulator paradigm — modulating gene expression over days. They are complementary, not interchangeable. Using Cortagen with the expectation of Semax-like acute effects will lead to disappointment.

Cycling too frequently (less than 3 months between courses): The standard protocol spaces Cortagen cycles 3–6 months apart. The rationale is that bioregulatory effects on gene expression persist for months after the 10–20 day intensive course. Running cycles more frequently than every 3 months has not been studied and does not align with the established paradigm.

Ignoring the limited Western evidence base: Most Cortagen research comes from Khavinson’s group and Russian/CIS institutions. While some publications appear in international journals, there are no large-scale independent Western replications. Users should factor this evidence gap into their decision-making rather than treating the available data as equivalent to extensively replicated Western clinical trials.

Using excessively high doses without clinical guidance: The established dosage range for Cortagen is 1–10 mg daily. Exceeding 10 mg per day has not been studied and does not follow published protocols. Higher doses do not necessarily produce greater bioregulatory effects — the peptide paradigm relies on signaling at physiological concentrations, not dose-dependent pharmacological effects.

Storing reconstituted peptide improperly: Cortagen must be refrigerated after reconstitution (2–8°C) and used within 20–28 days. Leaving reconstituted peptide at room temperature accelerates degradation. Given that Cortagen cycles are 10–20 days, a single reconstituted vial should be used within the cycle if properly stored.

Not combining with other bioregulators when pursuing longevity goals: Khavinson’s research emphasizes using tissue-specific bioregulators in combination for systemic anti-aging benefits. Using Cortagen alone for longevity misses the broader protocol, which typically includes Epitalon (pineal), Pinealon (brain), and other tissue-specific peptides. If your goal is longevity, consider the full bioregulator stack.

Frequently Asked Questions

Key Takeaways

Cortagen (Ala-Glu-Asp-Pro) is a cerebral cortex bioregulator — a synthetic tetrapeptide developed by Khavinson, theorized to modulate gene expression specifically in cortical neurons
Standard dose: 1–10 mg SubQ daily for 10–20 days — 1–3 mg for nootropic support, 5–10 mg for neurological support
Cycle every 3–6 months: Short intensive courses followed by months-long breaks — the standard Khavinson bioregulator paradigm
Different paradigm from conventional nootropics: Cortagen targets gene expression, not acute receptor signaling. Effects develop over the 10–20 day cycle and are theorized to persist for months
Best stacked with: Epitalon (longevity), Pinealon (broader CNS), Semax (acute nootropic), or Cerebrolysin (neurotrophic — medical supervision required)
Extremely mild side effect profile — rare injection site reactions and occasional mild headache. No hormonal disruption, no appetite changes, no water retention
Evidence base is moderate-to-limited: Primarily Russian/CIS publications from Khavinson's group. Some international peer-reviewed publications but limited independent Western replication
Not FDA-approved — classified as a research peptide in most Western countries. Available as a dietary supplement in Russia. Check local regulations.
Morning administration preferred — aligns with cortical activity during the waking period. Fasting not strictly required but some practitioners prefer it.
Complete the full cycle: Do not skip days during the 10–20 day course. The bioregulatory theory depends on sustained daily exposure to trigger the gene expression cascade.

This article is for educational and informational purposes only. See our Disclaimer.

References

Khavinson VK. “Peptides and Ageing.” Neuroendocrinology Letters. 2002;23(Suppl 3):11-144. PubMed
Khavinson VK, Malinin VV. “Gerontological aspects of genome peptide regulation.” Karger, Basel. 2005.
Khavinson VK, et al. “Tetrapeptide Ala-Glu-Asp-Pro as a neuroprotective agent.” Bull Exp Biol Med. 2006;141(4):430-432.
Khavinson VK, et al. “Peptide bioregulators: A new class of geroprotectors. Message 1: Results of experimental studies.” Adv Gerontol. 2012;2(3):177-186. PubMed
Khavinson VK, et al. “Short peptides modulate the effect of endonucleases of wheat germ.” Bull Exp Biol Med. 2010;150(1):67-69.
Anisimov VN, Khavinson VK. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139-149. PubMed
Khavinson VK, et al. “Mechanism of biological activity of short peptides: Cell penetration and epigenetic regulation of gene expression.” Biology Bulletin Reviews. 2013;3(6):451-455.
Chalisova NI, et al. “Short peptides stimulate cell regeneration in cerebral cortex tissue culture.” Bull Exp Biol Med. 2014;158(1):126-128.
Khavinson VK, et al. “AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism.” Molecules. 2020;25(3):609. PubMed
Fedoreyeva LI, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry (Moscow). 2011;76(11):1210-1219. PubMed

Next Steps

Continue your research with these resources.

Epitalon Dosage Guide

Learn dosing protocols for Epitalon — the pineal gland bioregulator for telomerase activation, commonly stacked with Cortagen.

Read Guide

Dosage Calculator

Calculate your exact Cortagen dose based on vial size and reconstitution volume.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory